Asacol™ (mesalazine) is a medicine for the treatment of the inflamed lining of the large bowel (colonic and rectal mucosa) and is prescribed as a first-line treatment for mild to moderate ulcerative colitis (UC). Asacol is available in tablets in 400 and 800 mg strengths as well as enemas and suppositories.
Asacol is available in 50 countries worldwide as Asacol and as Octasa®, Asacolon™ and Fivasa™ in the UK, Ireland and France, respectively. Specific indications and instructions for use vary by country.
Asacol 1600 mg (mesalazine) incorporates the modern OPTICORE technology and is indicated for the treatment of mild to moderate UC. Asacol 1600 is currently available in Denmark, Iceland and Norway under the brand name Asacol and in the Netherlands under the brand name Yaldigo.
Asacol 1600: Important information on ASACOL™ 1600 mg and its use can be found in the summary of product characteristics (SmPC)
Last update: January 2019.
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, OPTICORE™, Octasa™, Fivasa™, Yaldigo™, Kiudro™, Lixacol™, Asacolon™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™, Budecol™ and Zentacort™ are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries). The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The product rights to Asacol 1600 mg are owned by Tillotts globally, with the trademark varying from country to country. OPTICORE™ has been developed based on the Phloral™ technology.
Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.